Atossa Therapeutics, Inc. (ATOS)
| Market Cap | 121.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.91M |
| Shares Out | 125.80M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,041,280 |
| Open | 0.970 |
| Previous Close | 0.980 |
| Day's Range | 0.960 - 1.020 |
| 52-Week Range | 0.730 - 2.310 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+626.37%) |
| Earnings Date | Nov 12, 2024 |
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ATOS stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 626.37% from the latest price.
News
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer Treatments Insil...
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of ...
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Novel Compounds Demonstrate Promising Anti-Tumor Activity in Estrogen Receptor-Positive (ERα+) Breast Cancer, Including Endocrine-Resistant Tumors Novel Compounds Demonstrate Promising Anti-Tumor Acti...
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference Detailed results from the KARIS...
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) a clinical-stage biopharmaceutical company developing innovative medicines for breast ca...
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa's Mission in Developing Innovative Breast Cancer Therapies Dr. Lopez Brings 20+ Years of Global Clinical Deve...
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, wi...
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will...
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum
SEATTLE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its recognition and support of Breast Cancer Awareness Month this Octob...
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
FDA Update to Mammography Regulations in MQSA Final Rule is Effective Today FDA Update to Mammography Regulations in MQSA Final Rule is Effective Today
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its participation in the H.C. Wainwright 26th Annual Global Investment...
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has granted ...
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
Seattle, WA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SEATTLE, August 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborati...
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks bring...
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended June 30, 2024, and provid...
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase...
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company's new Chief Financial Of...
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate Atossa's ...
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according t...
Atossa to Present at the Sidoti Small-Cap Investor Conference
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conferen...
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, arti...